Related Experiment Video
Updated: May 15, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Pathophysiology and molecular aspects of diffuse large B-cell lymphoma
Gisele Rodrigues Gouveia1, Sheila Aparecida Coelho Siqueira, Juliana Pereira
1Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo - USP, São Paulo, SP, Brazil.
Revista Brasileira De Hematologia E Hemoterapia
|January 17, 2013
Summary
Diffuse large B-cell lymphoma (DLBCL) is a common cancer. While anti-CD20 antibodies improve survival, 50% of patients remain incurable, necessitating further research into DLBCL pathogenesis.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in Western countries and a significant cause of cancer in Brazil.
- Advances in immunology and molecular medicine have shifted DLBCL classification from morphology to a biological basis.
- DLBCL pathogenesis is multifactorial, involving genetic, environmental, occupational, and dietary factors.
Purpose of the Study:
- To elucidate the key factors and molecular pathways implicated in the pathogenesis of diffuse large B-cell lymphoma.
- To highlight the current treatment landscape and the unmet need for novel therapeutic strategies in DLBCL.
Main Methods:
- Review of current literature on DLBCL classification, pathogenesis, and treatment.
- Analysis of molecular alterations including oncogene activation (BCL2, BCL6, MYC) and tumor suppressor gene inactivation (p53, INK4).
Main Results:
- The anti-CD20 monoclonal antibody combined with the CHOP regimen has improved overall survival by 20% in DLBCL and follicular lymphoma patients.
- Despite treatment advances, 50% of DLBCL patients remain incurable, underscoring the need for new therapeutic approaches.
Conclusions:
- Understanding the complex molecular pathogenesis of DLBCL is crucial for developing more effective treatments.
- Further research into novel therapeutic targets and strategies is essential to improve outcomes for all DLBCL patients.
Related Concept Videos
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:11IP3/DAG Signaling Pathway
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...